These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 15664013)

  • 1. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.
    Misof BM; Roschger P; Baldini T; Raggio CL; Zraick V; Root L; Boskey AL; Klaushofer K; Fratzl P; Camacho NP
    Bone; 2005 Jan; 36(1):150-8. PubMed ID: 15664013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
    Boskey AL; Marino J; Spevak L; Pleshko N; Doty S; Carter EM; Raggio CL
    Clin Orthop Relat Res; 2015 Aug; 473(8):2587-98. PubMed ID: 25903941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model.
    McCarthy EA; Raggio CL; Hossack MD; Miller EA; Jain S; Boskey AL; Camacho NP
    Pediatr Res; 2002 Nov; 52(5):660-70. PubMed ID: 12409511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice.
    Camacho NP; Carroll P; Raggio CL
    Calcif Tissue Int; 2003 May; 72(5):604-9. PubMed ID: 12574874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.
    Bargman R; Posham R; Boskey AL; DiCarlo E; Raggio C; Pleshko N
    Osteoporos Int; 2012 Mar; 23(3):1141-50. PubMed ID: 21901481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta.
    Camacho NP; Raggio CL; Doty SB; Root L; Zraick V; Ilg WA; Toledano TR; Boskey AL
    Calcif Tissue Int; 2001 Aug; 69(2):94-101. PubMed ID: 11683430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta.
    Shi C; Sun B; Ma C; Wu H; Chen R; He H; Zhang Y
    Biomed Res Int; 2021; 2021():4243105. PubMed ID: 33506016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta.
    Shi C; Hu B; Guo L; Cao P; Tian Y; Ma J; Chen Y; Wu H; Hu J; Deng L; Zhang Y; Yuan W
    J Bone Miner Res; 2016 May; 31(5):1003-14. PubMed ID: 26679066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.
    Cardinal M; Dessain A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
    Calcif Tissue Int; 2020 May; 106(5):494-508. PubMed ID: 32025752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation.
    Uveges TE; Kozloff KM; Ty JM; Ledgard F; Raggio CL; Gronowicz G; Goldstein SA; Marini JC
    J Bone Miner Res; 2009 May; 24(5):849-59. PubMed ID: 19113917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta.
    Cardinal M; Tys J; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
    Bone; 2019 Jul; 124():137-147. PubMed ID: 31051315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raloxifene reduces skeletal fractures in an animal model of osteogenesis imperfecta.
    Berman AG; Wallace JM; Bart ZR; Allen MR
    Matrix Biol; 2016; 52-54():19-28. PubMed ID: 26707242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta.
    Delos D; Yang X; Ricciardi BF; Myers ER; Bostrom MP; Camacho NP
    J Orthop Res; 2008 Feb; 26(2):153-64. PubMed ID: 17729310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combined elcatonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats.
    Ogawa K; Hori M; Takao R; Sakurada T
    J Bone Miner Metab; 2005; 23(5):351-8. PubMed ID: 16133684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic impact of low amplitude high frequency whole body vibrations on the osteogenesis imperfecta mouse bone.
    Vanleene M; Shefelbine SJ
    Bone; 2013 Apr; 53(2):507-14. PubMed ID: 23352925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The material basis for reduced mechanical properties in oim mice bones.
    Camacho NP; Hou L; Toledano TR; Ilg WA; Brayton CF; Raggio CL; Root L; Boskey AL
    J Bone Miner Res; 1999 Feb; 14(2):264-72. PubMed ID: 9933481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta.
    Evans KD; Lau ST; Oberbauer AM; Martin RB
    Bone; 2003 Mar; 32(3):268-74. PubMed ID: 12667554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal mineral-matrix interactions are a significant contributor to fragility in oim/oim bone.
    Miller E; Delos D; Baldini T; Wright TM; Pleshko Camacho N
    Calcif Tissue Int; 2007 Sep; 81(3):206-14. PubMed ID: 17660935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of alendronate and strontium ranelate on cancellous and cortical bone mass in glucocorticoid-treated adult rats.
    Sun P; Cai DH; Li QN; Chen H; Deng WM; He L; Yang L
    Calcif Tissue Int; 2010 Jun; 86(6):495-501. PubMed ID: 20390406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
    Ward LM; Rauch F; Whyte MP; D'Astous J; Gates PE; Grogan D; Lester EL; McCall RE; Pressly TA; Sanders JO; Smith PA; Steiner RD; Sullivan E; Tyerman G; Smith-Wright DL; Verbruggen N; Heyden N; Lombardi A; Glorieux FH
    J Clin Endocrinol Metab; 2011 Feb; 96(2):355-64. PubMed ID: 21106710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.